Position statement – The need for efficacy evidence of edaravone

The UK MND Clinical Studies Group, having reviewed the available evidence on the efficacy of edaravone, has agreed the following position statement:

The CSG believes a properly designed, randomised placebo-controlled phase 3 trial of oral edaravone is required to determine the treatment's efficacy.

Aleksandar Radunovic, Consultant Neurologist

Amina Chaouch, Consultant Neurologist

Ammar Al Chalabi, Consultant Neurologist

Andrea Malaspina, Consultant Neurologist

Ashwin Pinto, Consultant Neurologist

Brian Dickie, Research Director, MND Association

Carolyn Young, Consultant Neurologist

Chris McDermott, Consultant Neurologist

Christina Faull, Palliative Care Consultant

George Gorrie, Consultant Neurologist

Hisham Hamdalla, Consultant Neurologist

Ian Morrison, Consultant Neurologist

Janine Vince, Lay Advisor (family carer of patient with MND)

John Ealing, Consultant Neurologist

Karen Morrison, Consultant Neurologist

Kevin Talbot, Consultant Neurologist

Lisa Milella, Lay Advisor (patient with MND)

Martin Turner, Consultant Neurologist

Mary O’Brien, Professor of Palliative and Support Care

Muhammad Rafiq, Consultant Neurologist

Nick Cole, Head of Research, MND Association

Nicola Drewry, Lay Advisory (patient with MND)

Nigel Leigh, Consultant Neurologist

Oliver Hanemann, Consultant Neurologist

Pamela Shaw, Consultant Neurologist

Rhys Roberts, Consultant Neurologist

Richard Davenport, Consultant Neurologist

Richard Orrell, Consultant Neurologist

Siddharthan Chandran, Consultant Neurologist

Stacy Young, Clinical Research Manager

Suresh Chhetri, Consultant Neurologist

Tim Williams, Consultant Neurologist

UK MND CSG – Oral edaravone position statement (PDF, 177KB)